JP6783777B2 - 二次感染の予防方法 - Google Patents

二次感染の予防方法 Download PDF

Info

Publication number
JP6783777B2
JP6783777B2 JP2017541661A JP2017541661A JP6783777B2 JP 6783777 B2 JP6783777 B2 JP 6783777B2 JP 2017541661 A JP2017541661 A JP 2017541661A JP 2017541661 A JP2017541661 A JP 2017541661A JP 6783777 B2 JP6783777 B2 JP 6783777B2
Authority
JP
Japan
Prior art keywords
infection
mmp
ecm
influenza
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017541661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507847A (ja
JP2018507847A5 (enExample
Inventor
イリット サギ，
イリット サギ，
ダリット タルミ−フランク，
ダリット タルミ−フランク，
イナ ソロモノヴ，
イナ ソロモノヴ，
イド アミット，
イド アミット，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2018507847A publication Critical patent/JP2018507847A/ja
Publication of JP2018507847A5 publication Critical patent/JP2018507847A5/ja
Application granted granted Critical
Publication of JP6783777B2 publication Critical patent/JP6783777B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2017541661A 2015-02-09 2016-02-09 二次感染の予防方法 Expired - Fee Related JP6783777B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113551P 2015-02-09 2015-02-09
US62/113,551 2015-02-09
PCT/IL2016/050156 WO2016128975A1 (en) 2015-02-09 2016-02-09 Methods of preventing secondary infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020177658A Division JP7109515B2 (ja) 2015-02-09 2020-10-22 二次感染の予防方法

Publications (3)

Publication Number Publication Date
JP2018507847A JP2018507847A (ja) 2018-03-22
JP2018507847A5 JP2018507847A5 (enExample) 2019-03-22
JP6783777B2 true JP6783777B2 (ja) 2020-11-11

Family

ID=56615084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017541661A Expired - Fee Related JP6783777B2 (ja) 2015-02-09 2016-02-09 二次感染の予防方法
JP2020177658A Expired - Fee Related JP7109515B2 (ja) 2015-02-09 2020-10-22 二次感染の予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020177658A Expired - Fee Related JP7109515B2 (ja) 2015-02-09 2020-10-22 二次感染の予防方法

Country Status (7)

Country Link
US (2) US10610588B2 (enExample)
EP (1) EP3256135A4 (enExample)
JP (2) JP6783777B2 (enExample)
BR (1) BR112017017115A2 (enExample)
CA (1) CA2974925C (enExample)
HK (1) HK1244667A1 (enExample)
WO (1) WO2016128975A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3256135A4 (en) 2015-02-09 2018-06-27 Yeda Research and Development Co. Ltd. Methods of preventing secondary infections
USD841023S1 (en) * 2017-08-24 2019-02-19 Domo, Inc. Display screen or portion thereof with a graphical user interface
WO2021257894A1 (en) * 2020-06-19 2021-12-23 Board Of Regents, The University Of Texas System Anti-bst2 antibodies targeting bst2 long isoform

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
WO2004064728A2 (en) * 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
EP1624866A2 (en) 2003-05-16 2006-02-15 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
US7910620B2 (en) * 2005-04-22 2011-03-22 Broadhurst Iii Jack J Uses of neuraminidase inhibitors in infectious diseases
WO2015031654A2 (en) * 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
EP3256135A4 (en) 2015-02-09 2018-06-27 Yeda Research and Development Co. Ltd. Methods of preventing secondary infections

Also Published As

Publication number Publication date
EP3256135A4 (en) 2018-06-27
JP2018507847A (ja) 2018-03-22
US20200261577A1 (en) 2020-08-20
CA2974925C (en) 2022-03-22
US20180028650A1 (en) 2018-02-01
US11400156B2 (en) 2022-08-02
JP2021020936A (ja) 2021-02-18
HK1244667A1 (zh) 2018-08-17
CA2974925A1 (en) 2016-08-18
JP7109515B2 (ja) 2022-07-29
WO2016128975A1 (en) 2016-08-18
US10610588B2 (en) 2020-04-07
BR112017017115A2 (pt) 2018-04-03
EP3256135A1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
Genschmer et al. Activated PMN exosomes: pathogenic entities causing matrix destruction and disease in the lung
Bertuzzi et al. The pH-responsive PacC transcription factor of Aspergillus fumigatus governs epithelial entry and tissue invasion during pulmonary aspergillosis
Silva et al. Analysis of exosome release and its prognostic value in human colorectal cancer
Hui et al. Significance of dysregulated metadherin and microRNA-375 in head and neck cancer
JP7109515B2 (ja) 二次感染の予防方法
Kennedy et al. Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells
EP2285989B1 (en) Novel targets for regulation of angiogenesis
US20240165145A1 (en) Compositions and methods for treating cancer and biomarkers to detect cancer stem cell reprogramming and progression
Kim et al. Histone deficiency and accelerated replication stress in T cell aging
US20100074897A1 (en) Methods and Compositions related to HIF-1 alpha
Chatterjee et al. Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface
Wu et al. Increased expression of DRAM1 confers myocardial protection against ischemia via restoring autophagy flux
Konwar et al. Risk-focused differences in molecular processes implicated in SARS-CoV-2 infection: corollaries in DNA methylation and gene expression
Chiang et al. R1R2 peptide ameliorates pulmonary fibrosis in mice through fibrocyte migration and differentiation
Mousavi et al. Role of fibroblast activation protein alpha in fibroblast-like synoviocytes of rheumatoid arthritis
Shi et al. ABTB1 facilitates the replication of influenza A virus by counteracting TRIM4-mediated degradation of viral NP protein
Yu et al. Circ_0027791 contributes to the growth and immune evasion of hepatocellular carcinoma via the miR‐496/programmed cell death ligand 1 axis in an m6A‐dependent manner
US20230057430A1 (en) Inhibition of tap63 regulated oncogenic long non-coding rnas (trolls) in the treatment of cancer
US20140274769A1 (en) Methods and compositions for treatment of breast cancer
US20220275371A1 (en) Use of rab7 gtpase (rab7) inhibitors in enhancing permeability of the blood brain barrier (bbb)
US20220251569A1 (en) Treatment and prevention of disease mediated by wwp2
US20250360126A1 (en) Targeting an enzyme required for acute myeloid leukemia
US20220002400A1 (en) Methods of Treating Influenza A Virus Infections
Chen et al. S100A10 downregulation inhibits the phagocytosis of Cryptococcus neoformans by murine brain microvascular endothelial cells
Yang et al. Targeting Piezo1 can improve endometrial fibrosis by inhibiting ferroptosis in endothelial cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201022

R150 Certificate of patent or registration of utility model

Ref document number: 6783777

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees